ONE-P TMS First Responders
Key facts
- Who runs it
- Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- D-Cycloserine (DCS)
- Placebo
- Intermittent Theta Burst Stimulation (iTBS)
- Record updated
- 19 August 2026
Who can take part
- Age
- 19 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- are outpatients between the ages of 19-60
- are voluntary and competent to consent
- are first responders (active, on leave or retired)
- have DSM-5 diagnosis of PTSD with a CAPS for DSM-5 (CAPS-5) score ≥ 25
- 17-item Hamilton Depression Rating Scale score ≤ 23
- have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
- if participating in psychotherapy, must have been in stable treatment for at least 1 month prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
- able to adhere to the treatment schedule
- Pass the TMS adult safety screening (TASS) questionnaire, and the MRI safety screening
Who cannot take part
- have a concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
- have failed a course of ECT in the current episode or previous episode
- have received rTMS for any previous indication
- have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
- have a Severe Substance Use Disorder (except tobacco) within the last three (3) months
- have a lifetime MINI diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
- have a MINI diagnosis of OCD, or mood disorder that is assessed by a study investigator to be primary and causing greater impairment than PTSD
- have a diagnosis of any personality disorder, assessed by a study investigator to be primary and causing greater impairment than MDD
- have any significant neurological disorder, history of seizure disorder (except those therapeutically induced by ECT), or any significant head trauma with clear radiological evidence of cerebrovascular injury on imaging
- allergy to DCS
- clinically significant laboratory abnormality, in the opinion of the one of the principal investigators or study physicians (including but not limited to abnormal blood urea nitrogen (BUN), creatinine, estimated glomerular filtration rate (eGFR))
- have active suicidal intent
- are pregnant
- currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant due to the potential to limit rTMS efficacy
- currently take dicumarol, gingko biloba, isoniazid, ethionamide, fluphenazine, metrizamide, tramadol, warfarin due to potential interactions with D-Cycloserine
- planned vaccination with Bacille Calmette-Guérin, cholera or typhoid or planned imaging procedure with an injectable die, within one week following the treatment days, due to potential interactions with DCS
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 19 and 60 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to examine the feasibility and tolerability of a one-day protocol of repetitive transcranial magnetic stimulation with D-cycloserine (DCS) as an augmentation strategy in first responders who have PTSD.
The 2 groups in the trial
- active aiTBS plus DCSTreatment being tested
Treatment: D-Cycloserine (DCS) and Intermittent Theta Burst Stimulation (iTBS)
- active aiTBS plus placebo DCSPlacebo, for comparison
Treatment: Placebo and Intermittent Theta Burst Stimulation (iTBS)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- One-day rTMS + D-cycloserine to Treat PTSD in First Responders
- Criteria questions
- Built from NCT07773935, who can take part
- Record updated
- 19 August 2026